In osteosarcoma, single-cell sequencing studies have demonstrated that MHC-I molecules are frequently downregulated, and this reduction in tumor immunogenicity constitutes a key mechanism of immune escape (24)
However, more clinical studies must be encouraged to evaluate whether these drugs can act as GSH system enhancers and cardioprotective agents in patients
Simply encouraging patients to engage in more pleasant activities may backfire if these activities provide immediate gratification without requiring effort or skill development
Increased vascular permeability and fluid accumulation in alveoli is due to the activities of these pro-inflammatory cytokines, resulting in respiratory failure (3, 5)
The treatment goals are to treat the underlying cause, limit further blood loss or malabsorption, avoid blood transfusions in haemodynamically stable patients, relieve symptoms, and improve quality of life [1]
On-Label vs Off-Label Use and Regulatory Considerations Because BPC-157 is not approved by the FDA for any indication, any human use is off-label or within research settings